Boston Scientific Corporation $BSX Shares Sold by Integrity Alliance LLC.

Integrity Alliance LLC. cut its stake in Boston Scientific Corporation (NYSE:BSX) by 71.6% in the fourth quarter, HoldingsChannel reports. The fund owned 5,258 shares of the medical equipment provider’s stock after selling 13,247 shares during the period. Integrity Alliance LLC.’s holdings in Boston Scientific were worth $501,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of BSX. Egerton Capital UK LLP lifted its holdings in Boston Scientific by 223.7% in the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after acquiring an additional 3,671,548 shares during the period. Alphinity Investment Management Pty Ltd acquired a new position in Boston Scientific in the fourth quarter valued at approximately $252,918,000. Marshall Wace LLP lifted its holdings in Boston Scientific by 30.7% in the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after acquiring an additional 2,301,383 shares during the period. Credit Agricole S A acquired a new position in Boston Scientific in the third quarter valued at approximately $204,812,000. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of Boston Scientific by 28.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 8,367,398 shares of the medical equipment provider’s stock worth $816,909,000 after buying an additional 1,837,480 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Down 1.6%

NYSE BSX opened at $48.32 on Friday. The business has a fifty day moving average price of $60.23 and a 200 day moving average price of $78.62. Boston Scientific Corporation has a one year low of $48.13 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The company has a market cap of $71.82 billion, a P/E ratio of 20.22, a P/E/G ratio of 0.90 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the prior year, the company earned $0.75 EPS. The firm’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts anticipate that Boston Scientific Corporation will post 3.37 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its shares are undervalued.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight/hold and lowered its outlook on the stock, citing rising uncertainty around the company’s electrophysiology business and WATCHMAN growth. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Reuters reported Boston Scientific hit a two-year low after flagging weaker demand for its WATCHMAN heart device, adding to investor concern that a core growth driver is slowing. Boston Scientific hits two-year low after flagging weaker demand for heart device
• Negative Sentiment: The company’s 2026 guidance was reiterated, but investors viewed it as underwhelming given the slowdown in WATCHMAN and softer urology demand, which hurt sentiment further. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
• Negative Sentiment: Analyst commentary from Zacks said Boston Scientific and Abbott both posted solid growth, but Boston Scientific is facing mounting operational pressures, which may be limiting upside near term. BSX vs. ABT: Which Medical Stock Has More Upside Potential?
• Positive Sentiment: Despite the selloff, Boston Scientific’s clinical pipeline remains active, with updates on the FARAPULSE PFA atrial fibrillation study and a painful diabetic neuropathy trial milestone that could support future growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation Boston Scientific Nears Key Data Milestone in Painful Diabetic Neuropathy Trial
• Positive Sentiment: Unusually large call-option buying suggests some traders are positioning for a rebound in BSX after the recent weakness. Investors Buy Large Volume of Call Options on Boston Scientific (NYSE:BSX)

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday. Bank of America reduced their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Leerink Partners reduced their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research note on Thursday. National Bank Financial set a $115.00 target price on Boston Scientific in a research note on Monday, February 2nd. Finally, UBS Group reduced their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $87.46.

Insider Activity at Boston Scientific

In related news, Director Cheryl Pegus bought 1,770 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director directly owned 1,770 shares in the company, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.